EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Repurposing Dihydroartemisinin to Combat Oral Squamous Cell Carcinoma, Associated with Mitochondrial Dysfunction and Oxidative Stress

Shanwei Shi, Huigen Luo, Yuna Ji, Huiya Ouyang, Zheng Wang, Xinchen Wang, Renjie Hu, Lihong Wang, Yun Wang, Juan Xia, Bin Cheng, Baicheng Bao und 3 weitere

Oxidative Medicine and Cellular Longevity · 2023

DOI: 10.1155/2023/9595201 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oxidative Medicine and Cellular Longevity, 2023. Verfasst von Shanwei Shi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Hospital of Stomatology, Guangdong Provincial Key Laboratory of Stomatology, Guanghua School of Stomatology, Institute of Stomatological Research, Su…. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Mouth Neoplasms, Head and Neck Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundamental Research Funds for the Central Universities, Guangdong Financial fund for High-Caliber Hospital Construction, Basic and Applied Basic Research Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oral squamous cell carcinoma (OSCC), with aggressive locoregional invasion, has a high rate of early recurrences and poor prognosis. Dihydroartemisinin (DHA), as a derivative of artemisinin, has been found to exert potent antitumor activity. Recent studies reported that DHA suppresses OSCC cell growth and viability through the regulation of reactive oxygen species (ROS) production and mitochondrial calcium uniporter. However, the mechanism underlying the action of DHA on OSCCs remains elusive. In the study, we observed that 159 genes were remarkably misregulated in primary OSCC tumors associated with DHA-inhibited pathways, supporting that OSCCs are susceptible to DHA treatment. Herein, our study showed that DHA exhibited promising effects to suppress OSCC cell growth and survival, and single-cell colony formation. Interestingly, the combination of DHA and cisplatin (CDDP) significantly reduced the toxicity of CDDP treatment alone on human normal oral cells (NOK). Moreover, DHA remarkably impaired mitochondrial structure and function, and triggered DNA damage and ROS generation, and activation of mitophagy. In addition, DHA induced leakage of cytochrome C and apoptosis-inducing factor (AIF) from mitochondria, elevated Bax/cleaved-caspase 3 expression levels and compromised Bcl2 protein expression. In the OSCC tumor-xenograft mice model, DHA remarkably suppressed tumor growth and induced apoptosis of OSCCs in vivo. Intriguingly, a selective mitophagy inhibitor Mdivi-1 could significantly reinforce the anticancer activity of DHA treatment. DHA and Mdivi-1 can synergistically suppress OSCC cell proliferation and survival. These data uncover a previously unappreciated contribution of the mitochondria-associated pathway to the antitumor activity of DHA on OSCCs. Our study shed light on a new aspect of a DHA-based therapeutic strategy to combat OSCC tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Squamous CellMouth NeoplasmsHead and Neck NeoplasmsHumansAnimalsMiceSquamous Cell Carcinoma of Head and NeckReactive Oxygen SpeciesCell Line, TumorCell ProliferationCisplatinOxidative StressApoptosisMitochondriaArtemisininsQuinazolinones

Substanzen

Reactive Oxygen SpeciesCisplatinartenimolArtemisinins3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinoneQuinazolinones

Autor:innen und Institutionen

  • Hospital of Stomatology, Guangdong Provincial Key Laboratory of Stomatology, Guanghua School of Stomatology, Institute of Stomatological Research, Sun Yat-sen University, Guangzhou, Guangdong Province, China.
  • Hospital of Stomatology, Department of Oral and Maxillofacial Surgery, Guangdong Provincial Key Laboratory of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, Guangdong Province, China.
  • National Engineering Research Center of JUNCAO Technology, Fujian Agriculture and Forestry University, Fuzhou, Fujian, China.

ORCID-Profile: Baoshan Xu

Förderung

  • Fundamental Research Funds for the Central Universities
  • Guangdong Financial fund for High-Caliber Hospital Construction
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • State Key Laboratory of Oral Diseases
  • Guangdong Provincial Key Laboratory of Stomatology
  • Sun Yat-sen University
  • National Natural Science Foundation of China

Zitieren

APA

Shi, S., Luo, H., Ji, Y., Ouyang, H., Wang, Z., Wang, X., Hu, R., Wang, L., Wang, Y., Xia, J., Cheng, B., Bao, B., Li, X., Liao, G., & Xu, B. (2023). Repurposing Dihydroartemisinin to Combat Oral Squamous Cell Carcinoma, Associated with Mitochondrial Dysfunction and Oxidative Stress. Oxidative Medicine and Cellular Longevity. https://doi.org/10.1155/2023/9595201

Vancouver

Shi S, Luo H, Ji Y, Ouyang H, Wang Z, Wang X, et al. Repurposing Dihydroartemisinin to Combat Oral Squamous Cell Carcinoma, Associated with Mitochondrial Dysfunction and Oxidative Stress. Oxidative Medicine and Cellular Longevity. 2023. doi:10.1155/2023/9595201

BibTeX
@article{Shi2023,
  author = {Shi, Shanwei and Luo, Huigen and Ji, Yuna and Ouyang, Huiya and Wang, Zheng and Wang, Xinchen and Hu, Renjie and Wang, Lihong and Wang, Yun and Xia, Juan and Cheng, Bin and Bao, Baicheng and Li, Xin and Liao, Guiqing and Xu, Baoshan},
  title = {Repurposing Dihydroartemisinin to Combat Oral Squamous Cell Carcinoma, Associated with Mitochondrial Dysfunction and Oxidative Stress},
  journal = {Oxidative Medicine and Cellular Longevity},
  year = {2023},
  doi = {10.1155/2023/9595201}
}
Kostenlos starten →